Mark Alan Goldberg, SVP, Product Development at SYNAGEVA BIOPHARMA CORP (GEVA), sold 4,417 shares at $51.35 ($224K) on 2013-03-01, disclosed to the SEC on 2013-03-06.
Scheduled sale ($224k) by SVP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.39 | 2,704 | $136K | 60.8% |
| 2 | $51.35 | 1,713 | $88K | 39.2% |
| Total | $50.76 avg | 4,417 | $224K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |